Table 1.
The relationship of ATP6V1F expression with clinicopathological variables of HCC
| Clinicopathological variables | ATP6V1F-low | ATP6V1F-high | P-value | |
|---|---|---|---|---|
| Status | Alive | 132 | 109 | 0.312 |
| Dead | 53 | 77 | ||
| Age | Mean (SD) | 58.7 (14. 1) | ||
| Median [MIN, MAX] | 60.2 (12.9) | 61[61, 85] | 0.014 | |
| 61 [17, 90] | 60 | |||
| Gender | FEMALE | 61 | 126 | |
| MALE | 124 | 81 | 0.971 | |
| ASIAN | 77 | 6 | ||
| BLACK | 11 | 91 | ||
| WHITE | 93 | 2 | ||
| AMERICAN INDIAN | ||||
| pT_stage | T1 | 102 | 0.456 | |
| T2 | 40 | |||
| T2b | 1 | |||
| T3 | 20 | 25 | ||
| T3a | 12 | 17 | ||
| T3b | 2 | 4 | ||
| T4 | 6 | 7 | ||
| TX | 1 | |||
| T2a | 1 | |||
| pN_stage | N0 | 123 | 129 | 0.249 |
| NX | 62 | 52 | ||
| N1 | ||||
| pM_stage | M0 | 128 | 138 | 0.381 |
| M1 | 2 | 2 | ||
| MX | 55 | 46 | ||
| pTNM_stage | I | 95 | 76 | 0.556 |
| II | 40 | 46 | ||
| III | 2 | 1 | ||
| IIIA | 27 | 38 | ||
| IIIB | 2 | 6 | ||
| IIIC | 3 | 6 | ||
| IV | 1 | 1 | ||
| IVB | 1 | 1 | ||
| IVA | 1 | |||
| Grade | G1 | 35 | 20 | 0.362 |
| G2 | 97 | 80 | ||
| G3 | 48 | 74 | ||
| G4 | 3 | 9 | ||
| New_tumor_ event_type | Primary | 7 | 0.003 | |
| Recurrence | 76 | |||
| Non-radiation | 128 | 0.267 | ||
| Radiation_therapy | Radiation | 1 | 0.535 | |
| Neoadjuvant | 1 | 1 | ||
| No neoadjuvant | 184 | 185 | 1 | |
| Chemotherapy | 15 | 14 | ||
| Chemotherapy: | 1 | |||
| Hormone Therapy | ||||
| Chemotherapy:Targeted | 1 | 1 | ||
| Molecular therapy | ||||
| Other. specify in notes | 1 | |||
| Ancillary | 1 | |||
| Chemotherapy:Hormone Therapy:Other specify in notes | 1 | |||
| Targeted Molecular therapy | 5 | 1 |